PF
PFBC
Preferred Bank
$99.30
+1.34%
$1.4B
No data for this timeframe.
Vol
Market Cap$1.4B
Cap SizeSmall Cap
Analyst ConsensusBuy (55%)
Inst. Holders8 funds
Inst. Value$169.6M
Inst. Activity1 buys / 1 sells
SEC Reports3
Recent Activity
Jun 1, 2026
Event
Losartan Potassium
WARNING: FETAL TOXICITY When pregnancy is detected, discontinue losartan potassium as soon as possib
May 20, 2026
SEC
Preferred Bank reported Q1 2026 EPS of $2.53, a 4.2% miss versus the consensus estimate of $2.64, and revenue of $73.6M.
PRESS-RELEASE — Impact 4/10
May 20, 2026
earnings
Preferred Bank Announces Recovery Settlement
<p>LOS ANGELES, May 20, 2026 (GLOBE NEWSWIRE) -- <strong>Preferred Bank (NASDAQ: PFBC)</strong>, (
Apr 22, 2026
SEC
Preferred Bank (PFBC) reported Q1 2026 earnings with EPS of $2.53, missing the $2.46 consensus estimate by 2.8% and down
PRESS-RELEASE — Impact 7/10
Apr 8, 2026
SEC
Preferred Bank announced plans to release its Q1 2026 earnings on April 22, 2026, with a conference call to follow. The
PRESS-RELEASE — Impact 3/10
Inst.
RENAISSANCE TECHNOLOGIES LLC — TRIM
49,755 shares ($4.7M)
Inst.
WELLS FARGO & COMPANY/MN — ADD
13,443 shares ($1.3M)
Price Targets
$103.75
+4.5% upside
Hold
Current $99.30
Low $100.00
Median $102.00
High $111.00
4 analysts
$100.00
$111.00
Analyst Ratings
2Strong Buy
4Buy
5Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 27, 2026 | Piper Sandler | MAINTAIN | Overweight → Overweight |
| Apr 2, 2026 | Piper Sandler | MAINTAIN | Overweight → Overweight |
| Jan 26, 2026 | Piper Sandler | MAINTAIN | Overweight → Overweight |
| Jan 26, 2026 | Stephens & Co. | MAINTAIN | Equal-Weight → Equal-Weight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $2.64 ▲ +2.8% | $2.59 — $2.72 | 5% YoY | 5 |
| Next Q | $2.71 ▲ +3.8% | $2.58 — $2.76 | -5% YoY | 5 |
| Current FY | $10.62 ▲ +2.3% | $10.45 — $10.75 | 2% YoY | 5 |
| Next FY | $11.21 ▲ +1.0% | $10.97 — $11.44 | 6% YoY | 5 |
Latest Reports
NEUTRAL
PRESS-RELEASE
4/10
Preferred Bank reported Q1 2026 EPS of $2.53, a 4.2% miss versus the consensus estimate of $2.64, and revenue of $73.6M.
May 20, 2026
BEARISH
PRESS-RELEASE
7/10
Preferred Bank (PFBC) reported Q1 2026 earnings with EPS of $2.53, missing the $2.46 consensus estimate by 2.8% and down
Apr 22, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $79.1M | — |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $46.7M | NEW |
| MORGAN STANLEY | $20.0M | — |
| TWO SIGMA INVESTMENTS, LP | $10.1M | DOUBLED |
| FMR LLC | $4.9M | DOUBLED |
8 institutional holders with $169.6M total value (1,795,667 shares) as of 2025-Q4. Top holders: VANGUARD, CHARLES, MORGAN.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 837,897 | $79.1M | 46.7% | — |
| 2 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 494,827 | $46.7M | 27.6% | NEW |
| 3 | MORGAN STANLEY | 211,840 | $20.0M | 11.8% | — |
| 4 | TWO SIGMA INVESTMENTS, LP | 106,494 | $10.1M | 5.9% | DOUBLED +101.6% |
| 5 | FMR LLC | 52,023 | $4.9M | 2.9% | DOUBLED +146.9% |
| 6 | RENAISSANCE TECHNOLOGIES LLC | 49,755 | $4.7M | 2.8% | TRIM -33.3% |
| 7 | BANK OF AMERICA CORP /DE/ | 29,388 | $2.8M | 1.6% | TRIM -36.7% |
| 8 | WELLS FARGO & COMPANY/MN | 13,443 | $1.3M | 0.7% | ADD +45.5% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 74,555 | 49,755 | -33.3% | $4.7M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 9,237 | 13,443 | +45.5% | $1.3M | 2025-Q4 |
| UBS Group AG | TRIM | 178,214 | 83,283 | -53.3% | $7.5M | 2025-Q3 |
| FMR LLC | DOUBLED | 17,017 | 42,022 | +146.9% | $3.8M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | TRIM | 61,857 | 39,149 | -36.7% | $3.5M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 51,128 | 103,094 | +101.6% | $8.9M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | ADD | 41,197 | 61,857 | +50.1% | $5.4M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | ADD | 36,670 | 51,128 | +39.4% | $4.3M | 2025-Q1 |
| CITADEL ADVISORS LLC | TRIM | 42,907 | 23,285 | -45.7% | $1.9M | 2025-Q1 |
| FMR LLC | DOUBLED | 7,356 | 17,656 | +140.0% | $1.5M | 2025-Q1 |
| UBS Group AG | DOUBLED | 16,585 | 203,168 | +1125.0% | $17.5M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 6,260 | 7,848 | +25.4% | $677.9K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 415,722 | — | $33.4M | 2024-Q3 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
3 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 2 neutral. Avg impact: 4.7/10.
NEUTRAL
PRESS-RELEASE
4/10
Preferred Bank reported Q1 2026 EPS of $2.53, a 4.2% miss versus the consensus estimate of $2.64, an
May 20, 2026
BEARISH
PRESS-RELEASE
7/10
Preferred Bank (PFBC) reported Q1 2026 earnings with EPS of $2.53, missing the $2.46 consensus estim
Apr 22, 2026
NEUTRAL
PRESS-RELEASE
3/10
Preferred Bank announced plans to release its Q1 2026 earnings on April 22, 2026, with a conference
Apr 8, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Hold (55% buy). Based on 11 analysts: 2 strong buy, 4 buy, 5 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$103.75 mean target
+4.5% upside
Hold (3.00)
$100.00 Low
$111.00 High
| Metric | Value |
|---|---|
| Current Price | $99.30 |
| Target Low | $100.00 |
| Target Mean | $103.75 |
| Target Median | $102.00 |
| Target High | $111.00 |
| # Analysts | 4 |
| Recommendation | Hold (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$2.64 | $2.59 | $2.72 | 4.8% | +2.8% | 5↑ 0↓ | $0.1B | 4.2% | 5 |
| Next Q 2026-09-30 |
$2.71 | $2.58 | $2.76 | -4.6% | +3.8% | 5↑ 0↓ | $0.1B | 0.6% | 5 |
| Current FY 2026-12-31 |
$10.62 | $10.45 | $10.75 | 2.1% | +2.3% | 5↑ 0↓ | $0.3B | 1.5% | 5 |
| Next FY 2027-12-31 |
$11.21 | $10.97 | $11.44 | 5.5% | +1.0% | 3↑ 1↓ | $0.3B | 7.5% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $2.640 | |
| 7d ago | $2.640 | |
| 30d ago | $2.568 | +0.072 |
| 60d ago | $2.546 | +0.094 |
| 90d ago | $2.560 | +0.080 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 27, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Apr 2, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Jan 26, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Jan 26, 2026 | Stephens & Co. | MAINTAIN | Equal-Weight | Equal-Weight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 4 | 5 | 0 | 0 | 55% | |
| May 1, 2026 | 2 | 4 | 5 | 0 | 0 | 55% | |
| Apr 1, 2026 | 2 | 4 | 5 | 0 | 0 | 55% | |
| Mar 1, 2026 | 2 | 4 | 5 | 0 | 0 | 55% | |
| Feb 1, 2026 | 2 | 4 | 4 | 0 | 0 | 60% | |
| Jan 1, 2026 | 3 | 4 | 4 | 0 | 0 | 64% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 1, 2026
FDA
Losartan Potassium
WARNING: FETAL TOXICITY When pregnancy is detected, discontinue losartan potassium as soon as possible. Drugs that act directly on the renin-angiotens
Jun 1, 2026
FDA
Losartan Potassium and Hydrochlorothiazide
WARNING: FETAL TOXICITY When pregnancy is detected, discontinue losartan potassium and hydrochlorothiazide tablets as soon as possible. Drugs that act
May 29, 2026
FDA
Losortan Potassium
WARNING: FETAL TOXICITY WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue l
May 29, 2026
FDA
Lorazepam
WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS • Concomitant use of benzodiaz
May 29, 2026
FDA
Losartan Potassium
WARNING: FETAL TOXICITY When pregnancy is detected, discontinue losartan Potassium tablets as soon as possible. Drugs that act directly on the renin-a
May 20, 2026
earnings
Preferred Bank Announces Recovery Settlement
<p>LOS ANGELES, May 20, 2026 (GLOBE NEWSWIRE) -- <strong>Preferred Bank (NASDAQ: PFBC)</strong>, (“the Bank”), an independent commercial bank, annou
Apr 23, 2026
short_interest
FTD: PFBC — 5,472 shares ($0.5M) failed to deliver
Settlement: 20260423, Price: $93.61, FTD Value: $512,233.92, PREFERRED BK LOS ANGELES CALIF
Apr 22, 2026
earnings
Preferred Bank Reports First Quarter Results
<p>LOS ANGELES, April 22, 2026 (GLOBE NEWSWIRE) -- <strong>Preferred Bank (NASDAQ: PFBC)</strong>, one of the larger independent California banks, t
Apr 22, 2026
earnings_calendar
PFBC Q1 2026 Earnings Scheduled — 2026-04-22
Apr 20, 2026
other
KBRA Affirms Ratings for Preferred Bank
<p>LOS ANGELES, April 20, 2026 (GLOBE NEWSWIRE) -- <strong>Preferred Bank (NASDAQ: PFBC)</strong>, (“the Bank”), an independent commercial bank, ann
Apr 8, 2026
earnings
Preferred Bank Announces 2026 First Quarter Earnings Release and Conference Call
<p>LOS ANGELES, April 08, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=STEsq-c0mBj1jydskI7siJbxXJk_KemXbuoSGB9scXxBI
Mar 18, 2026
dividend
Preferred Bank Announces Quarterly Dividend
<p>LOS ANGELES, March 18, 2026 (GLOBE NEWSWIRE) -- <strong>Preferred Bank (NASDAQ: PFBC)</strong>, one of the larger independent commercial banks in